These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38856086)

  • 1. Extended observation of reduced methamphetamine use with combined naltrexone plus bupropion in the ADAPT-2 trial.
    Li MJ; Chau B; Belin T; Carmody T; Jha MK; Marino EN; Trivedi M; Shoptaw SJ
    Addiction; 2024 Jun; ():. PubMed ID: 38856086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naltrexone plus bupropion reduces cigarette smoking in individuals with methamphetamine use disorder: A secondary analysis from the CTN ADAPT-2 trial.
    Schmitz JM; Stotts AL; Yoon JH; Northrup TF; Villarreal YR; Yammine L; Weaver MF; Carmody T; Shoptaw S; Trivedi MH
    J Subst Use Addict Treat; 2023 Aug; 151():208987. PubMed ID: 36822269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utilizing a Two-stage Design to Investigate the Safety and Potential Efficacy of Monthly Naltrexone Plus Once-daily Bupropion as a Treatment for Methamphetamine Use Disorder.
    Mooney LJ; Hillhouse MP; Thomas C; Ang A; Sharma G; Terry G; Chang L; Walker R; Trivedi M; Croteau D; Sparenborg S; Ling W
    J Addict Med; 2016; 10(4):236-43. PubMed ID: 27379819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bupropion and Naltrexone in Methamphetamine Use Disorder.
    Trivedi MH; Walker R; Ling W; Dela Cruz A; Sharma G; Carmody T; Ghitza UE; Wahle A; Kim M; Shores-Wilson K; Sparenborg S; Coffin P; Schmitz J; Wiest K; Bart G; Sonne SC; Wakhlu S; Rush AJ; Nunes EV; Shoptaw S
    N Engl J Med; 2021 Jan; 384(2):140-153. PubMed ID: 33497547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining behavioral harm-reduction treatment and extended-release naltrexone for people experiencing homelessness and alcohol use disorder in the USA: a randomised clinical trial.
    Collins SE; Duncan MH; Saxon AJ; Taylor EM; Mayberry N; Merrill JO; Hoffmann GE; Clifasefi SL; Ries RK
    Lancet Psychiatry; 2021 Apr; 8(4):287-300. PubMed ID: 33713622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A gender-based secondary analysis of the ADAPT-2 combination naltrexone and bupropion treatment for methamphetamine use disorder trial.
    Levander XA; Carmody T; Cook RR; Potter JS; Trivedi MH; Korthuis PT; Shoptaw S
    Addiction; 2023 Jul; 118(7):1320-1328. PubMed ID: 36864016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of extended-release injectable naltrexone and incentives for opiate abstinence in heroin-dependent adults in a model therapeutic workplace: A randomized trial.
    Jarvis BP; Holtyn AF; DeFulio A; Koffarnus MN; Leoutsakos JS; Umbricht A; Fingerhood M; Bigelow GE; Silverman K
    Drug Alcohol Depend; 2019 Apr; 197():220-227. PubMed ID: 30852374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sexual orientation differences among men in a randomized clinical trial of extended-release naltrexone and bupropion for methamphetamine use disorder.
    Kidd JD; Smiley SL; Coffin PO; Carmody TJ; Levin FR; Nunes EV; Shoptaw SJ; Trivedi MH
    Drug Alcohol Depend; 2023 Sep; 250():110899. PubMed ID: 37478502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism.
    Nunes EV; Bisaga A; Krupitsky E; Nangia N; Silverman BL; Akerman SC; Sullivan MA
    Addiction; 2020 Feb; 115(2):239-246. PubMed ID: 31313402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effects of Naltrexone on Subjective Response to Methamphetamine in a Clinical Sample: a Double-Blind, Placebo-Controlled Laboratory Study.
    Ray LA; Bujarski S; Courtney KE; Moallem NR; Lunny K; Roche D; Leventhal AM; Shoptaw S; Heinzerling K; London ED; Miotto K
    Neuropsychopharmacology; 2015 Sep; 40(10):2347-56. PubMed ID: 25801501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
    Krupitsky E; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Silverman BL
    Lancet; 2011 Apr; 377(9776):1506-13. PubMed ID: 21529928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methamphetamine/amphetamine use over time among persons with opioid use disorders treated with buprenorphine/naloxone versus extended-release naltrexone.
    Tsui JI; Campbell ANC; Pavlicova M; Choo TH; Lee JD; Cook RR; Shulman M; Nunes EV; Rotrosen J
    Drug Alcohol Depend; 2022 Jul; 236():109469. PubMed ID: 35605529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bupropion for the treatment of methamphetamine dependence in non-daily users: a randomized, double-blind, placebo-controlled trial.
    Anderson AL; Li SH; Markova D; Holmes TH; Chiang N; Kahn R; Campbell J; Dickerson DL; Galloway GP; Haning W; Roache JD; Stock C; Elkashef AM
    Drug Alcohol Depend; 2015 May; 150():170-4. PubMed ID: 25818061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence.
    Shoptaw S; Heinzerling KG; Rotheram-Fuller E; Steward T; Wang J; Swanson AN; De La Garza R; Newton T; Ling W
    Drug Alcohol Depend; 2008 Aug; 96(3):222-32. PubMed ID: 18468815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Greenway FL; Fujioka K; Plodkowski RA; Mudaliar S; Guttadauria M; Erickson J; Kim DD; Dunayevich E;
    Lancet; 2010 Aug; 376(9741):595-605. PubMed ID: 20673995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.
    Lee JD; Nunes EV; Novo P; Bachrach K; Bailey GL; Bhatt S; Farkas S; Fishman M; Gauthier P; Hodgkins CC; King J; Lindblad R; Liu D; Matthews AG; May J; Peavy KM; Ross S; Salazar D; Schkolnik P; Shmueli-Blumberg D; Stablein D; Subramaniam G; Rotrosen J
    Lancet; 2018 Jan; 391(10118):309-318. PubMed ID: 29150198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness implications of increasing the efficiency of the extended-release naltrexone induction process for the treatment of opioid use disorder: a secondary analysis.
    Murphy SM; Jeng PJ; McCollister KE; Leff JA; Jalali A; Shulman M; Lee JD; Nunes EV; Novo P; Rotrosen J; Schackman BR
    Addiction; 2021 Dec; 116(12):3444-3453. PubMed ID: 33950535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bupropion Slow Release vs Placebo With Adaptive Incentives for Cocaine Use Disorder in Persons Receiving Methadone for Opioid Use Disorder: A Randomized Clinical Trial.
    Ware OD; Sweeney MM; Cunningham C; Umbricht A; Stitzer M; Dunn KE
    JAMA Netw Open; 2023 Mar; 6(3):e232278. PubMed ID: 36920397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale.
    Lee JD; Nunes EV; Mpa PN; Bailey GL; Brigham GS; Cohen AJ; Fishman M; Ling W; Lindblad R; Shmueli-Blumberg D; Stablein D; May J; Salazar D; Liu D; Rotrosen J
    Contemp Clin Trials; 2016 Sep; 50():253-64. PubMed ID: 27521809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sociodemographic and patient reported outcomes by racial and ethnicity status among participants in a randomized controlled trial for methamphetamine use disorder.
    Okafor CN; Carmody T; Stotts AL; Bart G; Mayes TL; Karns-Wright T; Trivedi M; Shoptaw S; Potter JS
    Drug Alcohol Depend Rep; 2024 Jun; 11():100230. PubMed ID: 38665252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.